Investigational Device Labeling for U.S. Studies

Investigational device labeling is not simply a sticker applied before shipment. It is the controlled expression of the device’s regulatory status, permitted study use, risk information and handling restrictions.

A label that is technically correct can still create compliance problems if the instructions, packaging, recruitment materials or distribution process communicate something different.

Required Label Content Supports Regulatory Compliance

For investigations subject to FDA investigational-device requirements, the device or its immediate package must carry the required investigational-use statement, the responsible company’s name and place of business, and the quantity of contents where appropriate.

Other labeling must communicate relevant contraindications, hazards, adverse effects, warnings and precautions. It must not be false or misleading or represent that the device is safe or effective for the use under investigation.

These requirements also apply to nonsignificant-risk studies conducted under the abbreviated Investigational Device Exemption framework, even though the regulatory pathway and study approvals may differ.

The Label Must Match the Protocol

The controlled message must also match the protocol. Instructions for use, investigator training, device configuration, accessories, software version, treatment parameters, patient materials and study procedures should not authorize a use broader than the approved investigation.

Where a commercially distributed device is being studied, the team must clearly distinguish its cleared or approved commercial claims from the specific questions being investigated.

Study Communications Are Part of Labeling

FDA treats written, printed and graphic material accompanying a device broadly, and advertising may constitute labeling. Every communication that describes the device or investigation should therefore be controlled.

This includes recruitment advertisements, websites, presentations, emails, social-media posts, videos, and statements made by sponsor, site, distributor or agency personnel.

Recruitment materials should receive appropriate Institutional Review Board review and must not imply that the investigational device is proven, safe, effective, equivalent or superior. FDA has taken enforcement action where promotional claims appeared on public webpages while a device remained investigational.

Packaging and Distribution Complete the Labeling System

Study inventory should be segregated from commercial stock, packaged in the protocol-approved configuration, and traceable by study, site, lot or serial number, expiration date and labeling revision where applicable.

Superseded or incorrectly labeled units should be quarantined. Shipments should go only to authorized investigators or sites, with records supporting receipt, accountability, return, replacement, relabeling and final disposition.

Maintain a Single Regulatory Story

MDD Studies can establish and operate this study-specific control process by aligning the authorized study status, protocol, label set, packaging configuration and site instructions.

The model maintains segregated and traceable inventory, releases shipments only to authorized sites, and manages returns, replacements, relabeling and distribution exceptions.

This coordinated approach reduces the risk that the physical device, study records and sponsor communications tell different regulatory stories.